Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited has enhanced its board with the appointment of Noel Donnelly as a Non-Executive Director, bringing over 25 years of financial and operational leadership in the biopharmaceutical sector. Donnelly’s track record includes successful financial strategies, such as overseeing a $120M IPO for PepGen Inc., and advancing clinical assets, positioning him as a strategic asset for Radiopharm’s growth. The company, known for its innovative oncology radiopharmaceuticals, anticipates Donnelly’s expertise to be pivotal in its ongoing development and shareholder value creation.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.